Perrigo Company PLC (PRGO)
Receivables turnover
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
---|---|---|---|---|---|---|
Revenue | US$ in thousands | 4,373,400 | 4,655,600 | 4,451,600 | 4,138,700 | 5,063,300 |
Receivables | US$ in thousands | — | — | — | — | — |
Receivables turnover | — | — | — | — | — |
December 31, 2024 calculation
Receivables turnover = Revenue ÷ Receivables
= $4,373,400K ÷ $—K
= —
The data provided indicates that Perrigo Company PLC did not report any specific figures for receivables turnover for the years ending December 31, 2020 through December 31, 2024. As a result, it is not possible to analyze or interpret the receivables turnover ratio for Perrigo Company PLC based on the available information. The receivables turnover ratio is a key indicator of how efficiently a company is collecting payments from its customers, and without the necessary data, a comprehensive analysis of Perrigo's receivables turnover performance cannot be conducted at this time.
Peer comparison
Dec 31, 2024
Company name
Symbol
Receivables turnover
Perrigo Company PLC
PRGO
—
Abbott Laboratories
ABT
—
AbbVie Inc
ABBV
—
ACADIA Pharmaceuticals Inc
ACAD
—
Alkermes Plc
ALKS
4.05
Amphastar P
AMPH
5.37
ANI Pharmaceuticals Inc
ANIP
—
Arcus Biosciences Inc
RCUS
51.60
Biomarin Pharmaceutical Inc
BMRN
4.31
Bristol-Myers Squibb Company
BMY
4.49
Catalyst Pharmaceuticals Inc
CPRX
—